|Description||Binimetinib is an oral, highly selective MEK inhibitor.|
|Synonyms||MEK-162; MEK162; ARRY-162; ARRY162; ARRY 162; ARRY-438162|
|Current Developer||Array Biopharm./Novartis.|
U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.
PD98059 is a potent and selective inhibitor of MAP kinase kinase (also known as MAPK/ERK kinase or MEK kinase). It mediates its inhibitory properties by binding...
Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor RDEA119...
RO5126766, also known as CH5126766, is a protein kinase inhibitor specific for the Raf and MEK mitogen-activated protein kinases (MAPKs) with potential anti-ne...
SMK-17 is a MEK1/2 inhibitor. It can inhibit MEK1 kinase activity in a non-ATP-competitive manner and it is highly selective to MEK1 and 2. SMK-17 can inhibit t...
cobimetinib, also known as GDC-0973 and XL-518, is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1)...
RO4987655 is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK ...
Pimasertib, also known as AS703026, SAR245509, MSC1936369B, is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineop...
Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic acti...
Selective dual MEK5 and ERK5 (or BMK1) kinase inhibitor, with IC50 values of 1.5, 59, 580 and >6200 nM for MEK5, ERK5, TGFbR1 and other closely related kinases ...
GDC-0623 is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated pro...
Cobimetinib racemate is a selective inhibitor of MEK. It is also known as mitogen activated protein kinase kinase (MAPKK) and is a key component of the RAS/RAF/...
PD-0325901 i a potent bioavailable and selective MEK inhibitor, which targets mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential an...
Cobimetinib (R-enantiomer) is a selective inhibitor of MEK. It is also known as mitogen activated protein kinase kinase (MAPKK) and is a key component of the RA...
Selumetinib, also known as AZD6244, is an orally bioavailable small molecule with potential antineoplastic activity. Selumetinib inhibits mitogen-activated prot...
AZD8330 is an orally active, selective MEK inhibitor with potential antineoplastic activity. AZD8330 specifically inhibits mitogen-activated protein kinase kina...
Binimetinib is an oral, highly selective MEK inhibitor.
APS-2-79 is a small molecule antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site, and antagonizes oncogenic Ras signalling (I...
TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. MEK inhibitor TAK-733 selectively b...